ICAR- National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI), Karnataka, India.
Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Tamil Nadu, India.
J Vet Med Sci. 2023 Jul 17;85(7):755-762. doi: 10.1292/jvms.23-0021. Epub 2023 May 31.
The present study assessed the financial viability of Peste des Petits Ruminants (PPR) vaccine Research & Development (R&D) investment in India and the Gross Technology Revenue (GTR) accrual to the different stakeholders. The Net Present Value (NPV), Internal Rate of Return (IRR) and Benefit Cost Ratio (BCR) of PPR vaccine development and administration were USD 16,326.6 million (INR 130,612 crore), USD 184,54.2 million (INR 147,633 crore) and USD 21,645.6 million (INR 173,164 crore); 162.2%, 167.6% and 169.7% and 43.3:1, 48.8:1 and 57.1:1, respectively under low, medium and high disease incidence scenarios. The estimated cumulative GTR accrued during 2001-02 to 2017-18 by the innovating public research institutions (Indian Council of Agricultural Research-Indian Veterinary Research Institute (ICAR-IVRI) and Tamil Nadu Veterinary and Animal Sciences University (TANUVAS)), private vaccine producers, public sector biologicals and government revenues in terms of taxes was USD 0.696 million (INR 5.568 crore) for ICAR-IVRI and USD 0.033 million (INR 0.26 crore) for TANUVAS; USD 5.00 million (INR 40 crore); USD 7.141 million (INR 57.1 crore) and USD 0.671 million (INR 5.36 crore), respectively. Overall, financial benefits of PPR vaccine development and administration to control PPR in India outweighs the investment in manifolds.
本研究评估了在印度进行小反刍兽疫(PPR)疫苗研发投资的财务可行性,以及不同利益相关者获得的总技术收入(GTR)。PPR 疫苗研发和管理的净现值(NPV)、内部收益率(IRR)和效益成本比(BCR)分别为 1.63266 亿美元(13061.2 亿印度卢比)、1.84542 亿美元(14763.3 亿印度卢比)和 2.16456 亿美元(17316.4 亿印度卢比);在低、中、高疾病发生率情景下,分别为 162.2%、167.6%和 169.7%,43.3:1、48.8:1 和 57.1:1。根据 2001-02 年至 2017-18 年的估计,创新性公共研究机构(印度农业研究理事会-印度兽医研究所(ICAR-IVRI)和泰米尔纳德邦兽医和动物科学大学(TANUVAS))、私营疫苗生产商、公共部门生物制剂和政府税收获得的累积 GTR 分别为 0.696 亿美元(5.568 亿印度卢比)和 0.033 亿美元(0.26 亿印度卢比)ICAR-IVRI 和 TANUVAS;5000 万美元(4 亿印度卢比);714.1 万美元(57.1 亿印度卢比)和 671 万美元(5.36 亿印度卢比)。总体而言,在印度开发和管理 PPR 疫苗以控制 PPR 的财务收益超过了投资的多倍。